Vyne Therapeutics Inc (VYNE)

Q: Does VYNE pay dividends?

Vyne Therapeutics Inc (VYNE) has a dividend payment track record. See the VYNE dividend history page for its current payment status, TTM yield, and recorded payments.

Q: What is VYNE's market cap?

Vyne Therapeutics Inc (VYNE) has a market capitalization of $19.07M with a current stock price of $28.56.

Official site

HEALTHCARE • BIOTECHNOLOGY • NASDAQ

$28.56

+3.11 (+12.22%)

Market Cap: $19.07M

Last updated: Jul 27, 2026 at 5:00 PM ET

Earnings

Performance (10Y)

Beat Rate

61%(20/33)

Avg Surprise

+1.76%

Streak

1 Q

Last 12 of 37 reported quarters

Period	Reported	Est.	Range	Surprise	B/M	Analysts	Revisions	YoY
Jun 30, 2026Jun 26 Reported Aug 13, 2026Reported Aug 13	$N/A	$-0.18	$-0.18 - $-0.18	N/A	Beat	1	0 1 30d	-
Mar 31, 2026Mar 26 Reported May 15, 2026Reported May 15	$-0.08	N/A	-	N/A	Beat	1	0 1 30d	+99.2%
Dec 31, 2025Dec 25 Reported Mar 12, 2026Reported Mar 12	$-5.50	N/A	-	+52.17%	Beat	2	No revisions (30d)	-1849.0%
Sep 30, 2025Sep 25 Reported Nov 6, 2025Reported Nov 6	$-8.50	$-6.50	$-6.53 - $-6.47	-30.77%	Miss	2	No revisions (30d)	+41.4%
Jun 30, 2025Jun 25 Reported Aug 14, 2025Reported Aug 14	$-6.50	$-11.17	$-11.17 - $-11.17	+41.81%	Beat	0	No revisions (30d)	+40.9%
Mar 31, 2025Mar 25 Reported May 8, 2025Reported May 8	$-10.00	$-14.50	$-14.50 - $-14.50	+31.03%	Beat	0	No revisions (30d)	-6566.7%
Dec 31, 2024Dec 24 Reported Mar 6, 2025Reported Mar 6	$-0.28	$-0.30	$-0.33 - $-0.28	+6.96%	Beat	2	No revisions (30d)	+97.2%
Sep 30, 2024Sep 24 Reported Nov 7, 2024Reported Nov 7	$-14.50	$-11.75	$-11.78 - $-11.73	-23.40%	Miss	2	No revisions (30d)	+85.6%
Jun 30, 2024Jun 24 Reported Aug 14, 2024Reported Aug 14	$-11.00	$-9.50	$-9.50 - $-9.50	-15.79%	Miss	2	No revisions (30d)	+92.9%
Mar 31, 2024Mar 24 Reported May 9, 2024Reported May 9	$-0.15	$-0.24	$-0.24 - $-0.24	+37.50%	Beat	1	No revisions (30d)	+99.8%
Dec 31, 2023Dec 23 Reported Feb 29, 2024Reported Feb 29	$-10.00	N/A	-	+60.00%	Beat	1	No revisions (30d)	-200.3%
Sep 30, 2023Sep 23 Reported Nov 13, 2023Reported Nov 13	$-100.50	$-38.00	$-38.00 - $-38.00	-164.47%	Miss	1	No revisions (30d)	+20.2%

Dividends

Dividend Metrics

Forward Yield0.00%

Forward Annual Dividend$0.00

Pay MonthsJul

Key Metrics

Valuation
P/E Ratio	N/A	EV/EBITDA	N/A
Price/FCF	N/A	FCF Yield	N/A
Profitability
Profit Margin	0.00%	Operating Margin	-4437.00%
ROE	-63.20%	ROIC	N/A
Financial Health
Debt/Equity	N/A	Interest Coverage	N/A
Current Ratio	N/A	Quick Ratio	N/A
Trading Statistics
Beta	2.01	Avg Volume	N/A
52-Week High	$46.95	52-Week Low	$0.00

Technical Indicators Dashboard

Moving Averages

SMA 10$5.76

SMA 20$3.07

SMA 50$1.45

SMA 200$0.58

EMA 10$9.28

EMA 20$5.26

EMA 50$2.44

EMA 200$0.90

MACD

Line: 3.81Signal: 1.10Hist: 2.71

ADX

ADX: 36.9+DI: 298.8-DI: 4.3

Aroon & PSAR

Aroon Up100.0

Aroon Down96.0

PSAR$0.47

Bollinger Bands

Upper Band$19.47

Lower Band$-13.34

%B Position106967%(Upper)

Band Width1.28

RSI (14-Day)

Overbought

99.9

Momentum Oscillators

Stoch %K1798.9

Stoch %D1172.2

Williams %RN/A

ROC (10d)7673.5%

Momentum28.19

CCI (20d)527.1

MFI (14d)81.2

Volatility Measures

ATR (14d)$0.67(2.4%)

StdDev (20d)8.20

Hist Vol17153.6%(High)

Volume Flow

VWAP$26.83

OBV245.4M

AD Line-3.3B

CMF (20d)36.588

Volume Metrics

Avg Vol (20d)2.0M

Vol Ratio0.0x(Low)

VWMA (20d)$2.33

Pivot Points

R3$17.25

R2$8.90

R1$17.18

Pivot Point$8.82

S1$17.10

S2$8.74

S3$17.02

Advanced Oscillators

TSI99.16

Ultimate Osc357.6

KST12716.46

Financial Data

Quarter	Mar 2026	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024	Mar 2024	Dec 2023	Sep 2023	Jun 2023
Total Revenue	$86,000	$130,000	$169,000	$69,000	$202,000	$84,000	$121,000	$198,000	$98,000	$76,000	$114,000	$135,000
Cost of Revenue	$0	$5,000	$12,000	$0	$0	$4,000	$0	$0	$0	N/A	$0	$0
Gross Profit	$86,000	$130,000	$169,000	$69,000	$202,000	$84,000	$121,000	$198,000	$98,000	$76,000	$114,000	$135,000

Operating Expenses	$3.90M	$5.35M	$7.96M	$7.61M	$9.40M	$12.85M	$13.21M	$10.59M	$7.48M	$6.91M	$6.35M	$10.45M
R&D	$817,000	$2.98M	$5.26M	$4.88M	$6.12M	$9.68M	$10.25M	$7.31M	$3.71M	$3.02M	$3.32M	$7.23M
SG&A	$3.08M	$2.37M	$2.71M	$2.73M	$3.27M	$3.17M	$2.96M	$3.29M	$3.77M	$3.88M	$3.03M	$3.22M
Operating Income	$-3,816,000	$-5,219,000	$-7,792,000	$-7,542,000	$-9,197,000	$-12,770,000	$-13,091,000	$-10,396,000	$-7,380,000	$-6,831,000	$-6,234,000	$-10,318,000

Interest Income	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Interest Expense	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Income Before Tax	$-3,585,000	$-4,956,000	$-7,426,000	$-5,747,000	$-8,603,000	$-12,010,000	$-12,157,000	$-9,395,000	$-6,241,000	$-6,151,000	$-6,071,000	$-10,038,000
Income Tax Expense	$0	$4,000	$-146,000	$0	$0	$4,000	$0	$0	$0	$0	$0	$0

Net Income	$-3,585,000	$-4,837,000	$-7,280,000	$-5,755,000	$-8,611,000	$-12,022,000	$-12,157,000	$-9,406,000	$-6,249,000	$-6,188,000	$-6,584,000	$-10,058,000

EBITDA	$-3,597,000	$-4,951,000	$-7,420,000	$-5,955,000	$-8,921,000	$-12,554,000	$-12,663,000	$-10,011,000	$-7,018,000	$-6,406,000	$-6,071,000	$-10,038,000
EBIT	$-3,585,000	$-4,956,000	$-7,426,000	$-5,747,000	$-8,603,000	$-12,010,000	$-12,157,000	$-9,395,000	$-6,241,000	$-6,151,000	$-6,071,000	$-10,038,000

* Some calculated fields are derived from available data when not provided by source

Related GNG Research

No research available

Be the first to write about VYNE

News

VYNE stock trades quietly as investors look to recent dermatology trial data

VYNE Therapeutics' stock is trading in a narrow range as investors focus on its dermatology pipeline, particularly the recent clinical data on icotrokinra for inflammatory skin conditions. The company...

AD HOC NEWS•Sep 21, 2026 10:39 AM ET9/21/26•Somewhat-Bullish

VYNE Therapeutics stock holds steady as investors await next catalysts

VYNE Therapeutics stock is trading in a narrow range on Nasdaq, with a market capitalization of $120.0 million. The biotech company reported increased Q2 2026 revenue of $9.5 million, up 26.7% year-over-year...

AD HOC NEWS•Sep 20, 2026 10:31 AM ET9/20/26•Neutral

Yarrow Bioscience Reports Second Quarter 2026 Financial Results and Provides Business Update

Yarrow Bioscience announced its second quarter 2026 financial results, highlighting progress in its Phase 2a/2b clinical trial for YB-101...

BioSpace•Aug 13, 2026 7:12 PM ET8/13/26•Somewhat-Bullish

Yarrow Bioscience (VYNE) halves losses and completes transformative merger with Yarrow

Yarrow Bioscience (formerly VYNE Therapeutics) reported a significant reduction in its net loss for the six months ended June 30, 2026, dropping to $6.6 million from $14.4 million a year prior...

Stock Titan•Aug 13, 2026 4:11 PM ET8/13/26•Somewhat-Bullish

VYNE Profitability: Margins, ROIC and FCF

Operating margin: -4437.0%
Net margin: 0.0%
ROE: -63.2%

VYNE Competitors

Company	Ticker
Cocrystal Pharma Inc	COCP
Picard Medical, Inc.	PMI
Quoin Pharmaceuticals Ltd DRC	QNRX
Sensei Biotherapeutics Inc	SNSE
IGC Pharma, Inc.	IGC
Estrella Immunopharma Inc.	ESLA
Nano X Imaging Ltd	NNOX
Pasithea Therapeutics Corp	KTTA

Sector: Healthcare

VYNE Analyst Ratings

Consensus: Hold
Analysts: 3
Strong Buy: 0
Buy: 1
Hold: 2
Sell: 0
Strong Sell: 0

VYNE Bull Case vs Bear Case

Bear case

VYNE's quarterly revenue changed -57.4% year over year.

VYNE Earnings: Beat Rate and Next Report

Beat rate: 5 of 8 quarters (62.5%)
Average surprise: 8.9%

VYNE Dividend

Forward yield: 0.0%
Pay months: Jul

VYNE ETF Holders

GNG tracks 1 ETF that holds VYNE.

Vanguard Extended Market Index Fund ETF Shares (VXF), <0.01% of the fund

Open the ETF Stock Exposure tool for VYNE

See insider activity

Frequently Asked Questions About VYNE

Does VYNE pay dividends?